The RheumNow Week in Review - Nonadherence and Astronomic Costs (5.11.18) Save

Dr. Jack Cush reviews highlights, news and journal articles from the past week on RheumNow.com.

1. Australian RCT treated Trochanteric bursitis (glueal tendinopathy) w/ either education + exercise (EDX), steroid injx or "wait & see". EDX wins w/ better pain and global scores at wk 8 and better global scores at wk 52 (still less pain) https://t.co/eNky3xc9fW https://t.co/v6U8HRfqe0
2. In an animal model of induced large vessel vasculitis, in vivo Rx w/ tofacitinib reduced JAK2 & JAK 2 cytokine signaling and suppressed tissue-resident memory T cells and vasculitic pathology. https://t.co/7JIMbryFxo
3. AbbVie Submits Biologics License Application to FDA for Risankizumab (IL-23 Mab) for Moderate to Severe Plaque Psoriasis https://t.co/4lq3xKc6T1
4. FDA has approved 9 biosimilars in the USA> Zarxio, Inflectra, Erelzi, Amjevita, Renflexis, Cyltezo, Ixifi; Mvasi (Avastin), Ogivri (Herceptin). There are 5 more biosimilars (of either filgrastim or herceptin) in front of FDA w/ upcoming PDUFA dates https://t.co/jeQoGJmygF
5. The FDA may be getting into the EHR business; FDA has requested $100 million in FY2019 for an EHR initiative to evaluate the safety of regulated products. THis would connect patient safety and outcomes directly to the FDA. https://t.co/DuNorLFKr4
6. UK study of 1207 male ex-footballers & 4085 control pop. men shows knee osteoarthritis outcomes (knee pain, RKOA TKR) 2-3 times higher in male ex-footballers compared with men in the general population group https://t.co/FJQ34Dm84a
7. Patients May Not Fill Your Prescription   
8. Severity of Lupus Nephritis is Declining over Time  
9. 60 Minutes Drills Acthar - A Financially Crippling Drug   
10. "Not all symptoms merit a diagnosis or disease, some are just evidence of human imperfection" - J Cush, MD
11. "I'm addicted to placebos. I'd give them up, but it wouldn't make any difference."  - Steven Wright